GET DAILY SIGNALSWhy Is Candel Therapeutics (CADL) Stock Down -8.30% Today?
Key Takeaways
- CADL shares fell roughly 8.3% intraday, trading near $10.39 versus a prior session close of $11.33.
- The decline extended a multi-session pullback that included a 6.9% drop the previous day, unwinding a large portion of the stock's late-summer rally.
- No single company-specific headline drove the move; selling reflected profit-taking, financing and dilution concerns, and fading momentum after a run to a 52-week high of $14.00.
- Widening second-quarter losses and a 45% year-over-year rise in shares outstanding have kept capital-raise worries front and center.
- Trading volume was elevated, and the stock slipped below key short-term technical levels.
- Investors are watching the planned fourth-quarter BLA filing for aglatimagene in prostate cancer and progress in the Phase 3 AURORA lung cancer trial.
Opening Summary
Candel Therapeutics, Inc. (CADL), a clinical-stage biopharmaceutical company based in Needham, Massachusetts, that develops off-the-shelf viral immunotherapies for solid tumors, extended its recent downturn on Thursday. The stock was down approximately 8.3% in intraday trading, changing hands near $10.39 compared with a prior close of $11.33 — a decline of about $0.94 per share. The move confirmed a decisively lower session for a name that has now surrendered much of the ground gained during its summer surge.
Profit-Taking After a Sharp Run-Up
The most immediate driver behind the selloff appears to be profit-taking rather than a single adverse announcement. CADL rallied from a 52-week low of $4.35 to an intraday peak of $14.00 in late August, a gain of more than 200% in under a year, fueled by positive Phase 3 data for its lead candidate aglatimagene besadenovec in localized prostate cancer and the company's plan to submit a Biologics License Application (BLA) in the fourth quarter of 2026. After such a steep advance, momentum-oriented traders have been quick to lock in gains, and the stock has drifted lower through early September.
Financing and Dilution Concerns
Underlying the technical selling is a persistent concern about how a cash-consuming, pre-revenue biotech will fund its late-stage pipeline. Second-quarter results showed a net loss of $38.91 million, a sharp widening from a loss of roughly $4.8 million a year earlier. Meanwhile, shares outstanding have increased by about 45% over the past year, a reminder that Candel has repeatedly tapped equity markets to support its programs. Recent securities filings tied to a shelf registration and prior capital raises have kept dilution risk in the conversation, giving investors an incentive to reduce exposure during periods of weakness.
Technical Breakdown and Market Context
The two-day slide has carried CADL below its 50-day moving average, a level that had acted as support during the rally, and left the shares trading well off their late-August peak. Volume ran above the stock's recent average, indicating conviction behind the selling rather than an isolated bout of low-liquidity volatility. The move has diverged from the broader market, suggesting stock-specific and biotech-sector dynamics — including elevated short interest of roughly 16% of the float, which can amplify downward swings — are at work rather than a broad risk-off wave.
What Comes Next for CADL
Looking ahead, the investment thesis remains tied to execution. The company expects to file its BLA for aglatimagene in prostate cancer during the fourth quarter of 2026, a milestone that could refocus attention on the stock's fundamentals. It is also advancing the global Phase 3 AURORA trial of aglatimagene in advanced non-small cell lung cancer and expects long-term survival data from its linoserpaturev program in recurrent glioblastoma. Traders will also be watching for the next quarterly earnings report and any capital-raising announcements. Risks include clinical or regulatory setbacks, further dilution, and continued volatility driven by the stock's high short interest.
Trending AI Robots
Tickeron's Trending AI Robots page highlights the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Only the top performers are curated into this section, giving traders a way to explore automated approaches to the market. Visit the page to see which bots are leading today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
CADL's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for CADL moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 27 of the 27 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 69 cases where CADL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on CADL as a result. In 84 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for CADL just turned positive on October 28, 2026. Looking at past instances where CADL's MACD turned positive, the stock continued to rise in 36 of 42 cases over the following month. The odds of a continued upward trend are 86%.
Following a +11.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where CADL advanced for three days, in 213 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CADL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CADL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CADL entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. CADL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.490) is normal, around the industry mean (3.051). P/E Ratio (-6.156) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CADL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement